Elena Myasoedova
Rheumatology · Rochester, MNNPI 1235576232
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Every reported general payment came from a single manufacturer, Amgen. Reporting peaked in 2021 at $2,278 and has fallen 97.6% since, to $55 in 2025.
Across 6 payments — averaging $727.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
Across 2 payments — averaging $725,540 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.5M
What the payments were for
- Consulting fees$2,07348%
- Speaking & faculty fees$2,20551%
- Food & beverage$551%
- Education$301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 6 | $4,363 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,363 in reported general payments places this provider in the 80th percentile of 121 rheumatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrenciaAbatacept | 11 | $61,607 |
| Hydroxychloroquine Sulfate | 44 | $1,738 |
| MethotrexateMethotrexate Sodium | 50 | $1,486 |
| Prednisone | 59 | $676 |
| Sulfasalazine | 17 | $665 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Rochester
- Steven YtterbergRochester$87K
- Cornelia WeyandRochester$59K
- Eric MattesonRochester$51K
- John DavisRochester$32K
- Ashima MakolRochester$23K
- Kenneth WarringtonRochester$23K
- Elena JoernsRochester$10K
- Matthew KosterRochester$3K
- Mini BhaskarRochester$3K
- Can SungurRochester$618
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.